189 related articles for article (PubMed ID: 20548033)
1. Concomitant tumor and autoantigen vaccination supports renal cell carcinoma rejection.
Herbert N; Haferkamp A; Schmitz-Winnenthal HF; Zöller M
J Immunol; 2010 Jul; 185(2):902-16. PubMed ID: 20548033
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic tumor vaccination: comparison of effector mechanisms initiated by protein versus DNA vaccination.
Zöller M; Christ O
J Immunol; 2001 Mar; 166(5):3440-50. PubMed ID: 11207302
[TBL] [Abstract][Full Text] [Related]
3. Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma.
Kim BR; Yang EK; Kim DY; Kim SH; Moon DC; Lee JH; Kim HJ; Lee JC
Clin Exp Immunol; 2012 Jan; 167(1):73-83. PubMed ID: 22132887
[TBL] [Abstract][Full Text] [Related]
4. Enhancing whole-tumor cell vaccination by engaging innate immune system through NY-ESO-1/dendritic cell interactions.
Xu L; Zheng J; Nguyen DH; Luong QT; Zeng G
J Immunother; 2013 Oct; 36(8):412-22. PubMed ID: 23994888
[TBL] [Abstract][Full Text] [Related]
5. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
6. Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma.
Shimizu K; Uemura H; Yoshikawa M; Yoshida K; Hirao Y; Iwashima K; Saga S; Yoshikawa K
Oncol Rep; 2003; 10(5):1307-11. PubMed ID: 12883698
[TBL] [Abstract][Full Text] [Related]
7. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory activity of dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A for renal cell carcinoma.
Kim BR; Yang EK; Kim SH; Moon DC; Kim HJ; Lee JC; Kim DY
J Microbiol; 2011 Feb; 49(1):115-20. PubMed ID: 21369988
[TBL] [Abstract][Full Text] [Related]
9. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
[TBL] [Abstract][Full Text] [Related]
10. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
11. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination.
Weth R; Christ O; Stevanovic S; Zöller M
Cancer Gene Ther; 2001 Aug; 8(8):599-611. PubMed ID: 11571538
[TBL] [Abstract][Full Text] [Related]
12. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
14. An enhanced immune response against G250, induced by a heterologous DNA prime‑protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant.
Sun Z; Liu B; Ruan X; Liu Q
Mol Med Rep; 2014 Nov; 10(5):2657-62. PubMed ID: 25190325
[TBL] [Abstract][Full Text] [Related]
15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma.
Uemura H; Fujimoto K; Tanaka M; Yoshikawa M; Hirao Y; Uejima S; Yoshikawa K; Itoh K
Clin Cancer Res; 2006 Mar; 12(6):1768-75. PubMed ID: 16551861
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo.
Scheffer SR; Nave H; Korangy F; Schlote K; Pabst R; Jaffee EM; Manns MP; Greten TF
Int J Cancer; 2003 Jan; 103(2):205-11. PubMed ID: 12455034
[TBL] [Abstract][Full Text] [Related]
18. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.
Tüting T; Wilson CC; Martin DM; Kasamon YL; Rowles J; Ma DI; Slingluff CL; Wagner SN; van der Bruggen P; Baar J; Lotze MT; Storkus WJ
J Immunol; 1998 Feb; 160(3):1139-47. PubMed ID: 9570527
[TBL] [Abstract][Full Text] [Related]
19. Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Hernández JM; Bui MH; Han KR; Mukouyama H; Freitas DG; Nguyen D; Caliliw R; Shintaku PI; Paik SH; Tso CL; Figlin RA; Belldegrun AS
Clin Cancer Res; 2003 May; 9(5):1906-16. PubMed ID: 12738749
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
